Cardiol Launches $75M At-The-Market Program, Shares Slide
CRDL sits 20% above its 52-week low of $0.88 on light trading volume (0.3× avg).
Summary
Cardiol signed a US$75 million at-the-market sales agreement with Jefferies, letting it sell shares on Nasdaq at prevailing prices. The program sits under the US$150 million universal shelf registered in September, so it is a drawdown facility rather than a fresh registration. The size is large next to the company's roughly $127 million market cap, and the stock fell on the news as holders priced in dilution. Cash runway was already guided into the second half of 2027 after the September warrant exercises, so the raise is about funding the expanded Phase III MAVERIC trial rather than an immediate liquidity crunch.
At the time of this announcement, CRDL was trading at $1.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $126.7M. The 52-week trading range was $0.88 to $2.34. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.